Advanced age is considered to be an important risk factor for cancer. People over 65 years of age account for close to 60% of all new cancer cases and close to 70% of all cancer deaths. The rapidly aging global population is expected to further drive the demand for tissue diagnostic products by 2018. Furthermore, increasing research funding for cancer has helped underline the importance of personalized medicine for cancer treatment. Tissue diagnostic-based companion diagnostics kits enable the identification of patients most likely to benefit from candidate drug products. The increasing use of personalized medicine is expected to further drive the market for tissue diagnostic products.
Request a Sample copy @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=280675 .
The report segments the global tissue diagnostics market by technology, disease, product, end user, and geography. Immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, and special staining are the technology segments of the tissue diagnostics market included in this report. The disease segments included in this report are breast cancer, gastric cancer, lymphoma, prostate cancer, non-small-cell lung cancer (NSCLC), and other diseases segments. The end-user segments of the tissue diagnostics market included in this report are hospitals, pharmaceutical companies, research laboratories, contract research organizations, and other end users like reference laboratories. The report